Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archinte.1983.00350080029007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: New postoperative atrial fibrillation (POAF) occurs in about 40% after cardiac surgery. Mineralocorticoid receptor antagonists (MRA) are known to reduce chronic atrial fibrillation (AF) development and burden. We examined the impact of preoperative MRA use on POAF and also examine the atrial cell type impacted by MRA treatment during cold cardiac preservation.
View Article and Find Full Text PDFAnalysis of confounders on the image quality of a high-resolution isotropic 3D Dixon water-fat LGE technique.
J Cardiovasc Magn Reson
March 2025
Charité - Universitätsmedizin Berlin, corperate member of Freie Universität Berlin und Humbolt - Universität zu Berlin, ECRC Experimental and Clinical Research Center, Lindenberger Weg 80, 13125 Berlin, Germany; Working Group Cardiovascular Magnetic Resonance, Experimental and Clinical Research Center, Charité Medical Faculty, Max-Delbrück Center for Molecular Medicine, Helios Klinikum Berlin Buch, Department of Cardiology and Nephrology, Charité - Universitätsmedizin Berlin, Kardiologie - ECRC, Lindenberger Weg 80, 13125 Berlin, Germany; DZHK (German Center for Cardiovascular Research), Partner Site Berlin, Potsdamer Straße 58, 10785 Berlin, Germany. Electronic address:
Introduction: 3D water-fat separated LGE imaging is a cardiac magnetic resonance imaging technique allowing simultaneous assessment of and discrimination between cardiac fibrosis and myocardial fatty infiltration. The aim of this study is to systematically analyze the image quality of a 3D water-fat separated LGE research sequence and identify confounders of image quality.
Methods: In total 126 patients and 12 healthy volunteers were included.
Factor B as a therapeutic target for the treatment of complement-mediated diseases.
Front Immunol
March 2025
Service of Nephrology and Hypertension, Centre Hospitalier Universitaire Vaudois, UNIL, Lausanne, Switzerland.
The complement system, consisting of three initiating pathways-classical, lectin and alternative, is an important part of innate immunity. Dysregulation of the complement system is implicated in the pathogenesis of several autoimmune and inflammatory diseases. Therapeutic inhibition of the complement system has been recognized as a viable approach to drug development and has been successful with the approval of a small number of complement inhibitors for diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis and geographic atrophy.
View Article and Find Full Text PDFParoxysmal sympathetic hyperactivity and refractory hypotension in Guillain-Barré syndrome with autoimmune encephalitis: a case report and literature review.
Front Neurosci
February 2025
Department of Intensive Care Unit, Beijing Hui Min Hospital, Beijing, China.
Guillain-Barré syndrome (GBS) is an acute inflammatory peripheral nerve disorder mediated by autoimmune mechanisms. However, its co-occurrence with autoimmune encephalitis (AE) is rare. We present a 51-year-old man who initially presented with symmetrical numbness and weakness in all limbs, followed by hallucinations, behavioral abnormalities, and consciousness disturbances.
View Article and Find Full Text PDFRavulizumab and other complement inhibitors for the treatment of autoimmune disorders.
Mult Scler Relat Disord
March 2025
Neuroimaging Laboratory, Department of Neurology, Universidade Estadual de Campinas, Campinas, São Paulo, Brazil; Brazilian Institute of Neuroscience and Neurotechnology (BRAINN), Universidade Estadual de Campinas, Campinas, São Paulo, Brazil. Electronic address:
Ravulizumab (ULTOMIRIS™) an intravenous glycoengineered humanized anti-C5 IgG2/4 monoclonal antibody (mAb), is a new FDA-approved treatment for Aquaporin-4-antibody (AQP4-IgG) positive Neuromyelitis Optica Spectrum Disorder (NMOSD). Based on the importance of intermediate and terminal components of the complement cascade during disease pathogenesis, in the last few years, a mAb targeting the C5 complement factor (anti-C5, eculizumab) has already been in use for treating AQP4-IgG positive NMOSD. Ravulizumab acts similarly to eculizumab, binding specifically to the complement protein C5, thereby blocking the generation of the anaphylatoxin C5a and of C5b, which is crucial for generating the membrane attack complex (C5b-9).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!